C. Erlichman

发表

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

R. Mesa, D. Loegering, H. Powell, 2005, Blood.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

Erica K. Barnell, E. Mardis, O. Griffith, 2017, Clinical Cancer Research.

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

M. Ellis, F. Gao, J. Hoog, 2016, Clinical Cancer Research.

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

P. LoRusso, P. Fracasso, C. Erlichman, 2005, Cancer.

Molecular markers in male breast carcinoma

J. Donohue, J. Ingle, C. Erlichman, 1998, Cancer.

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors

C. James, J. Sarkaria, A. Bryce, 2012, Investigational New Drugs.

The Hsp90 chaperone complex as a novel target for cancer therapy.

M. Goetz, C. Erlichman, M. Ames, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathogenesis and Risk Factors of Small Bowel Adenocarcinoma: A Colorectal Cancer Sibling?

C. Erlichman, P. Limburg, T. Delaunoit, 2005, The American Journal of Gastroenterology.

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

T. Habermann, S. Ansell, I. Lowy, 2009, Clinical Cancer Research.

Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937).

C. Erlichman, B. Zee, L. Whitfield, 1991, Cancer research.

Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

J. Sloan, J. Sloan, E. Galanis, 2005, Gene Therapy.

Tanespimycin:theopportunities andchallengesoftargetingheat shockprotein90

C. Erlichman, 2009 .

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

C. Erlichman, P. Haluska, R. Qin, 2011, Investigational New Drugs.

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

A. Oberg, C. Erlichman, S. Kaufmann, 2012, Gynecologic oncology.

Comparison of Potential Markers of Farnesyltransferase Inhibition 1

C. Erlichman, S. Kaufmann, P. Svingen, 2000 .

A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups

D. Sargent, C. Erlichman, R. Qin, 2018, Journal of biopharmaceutical statistics.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

A. Tolcher, M. Goetz, K. Papadopoulos, 2015, Clinical Cancer Research.

Growth and characterization of multicellular tumor spheroids of human bladder carcinoma origin

I. Tannock, C. Erlichman, 1986, In Vitro Cellular & Developmental Biology.

Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

J. Sloan, J. Sloan, R. Goldberg, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors

M. Goetz, R. Lupu, C. Erlichman, 2017, Cancer Chemotherapy and Pharmacology.

Irinotecan in the treatment of glioma patients

J. O'fallon, J. Buckner, C. Erlichman, 2003, Cancer.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

B. Costello, J. Riess, B. Goh, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.

P. Goodman, C. Erlichman, J. Thiessen, 1993, Cancer research.

The role of plasma level monitoring in cancer chemotherapy

R. Donehower, C. Erlichman, 1981 .

Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.

Deborah A. Bowen, T. Shanafelt, C. Erlichman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).

D. Visscher, M. Goetz, N. Foster, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene expression pro fi ling identi fi es responsive patients with cancer of unknown primary treated with carboplatin , paclitaxel , and everolimus : NCCTG N 0871 ( alliance ) †

D. Visscher, M. Goetz, N. Foster, 2016 .

The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons*

D. Loegering, K. Flatten, N. T. Dai, 2005, Journal of Biological Chemistry.

Cisplatin abrogates the geldanamycin-induced heat shock response

C. Erlichman, W. Lingle, D. Toft, 2008, Molecular Cancer Therapeutics.

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

S. Mandrekar, G. Wilding, S. Alberts, 2005, Clinical Cancer Research.

APhase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor , PS-341 ( Bortezomib , Velcade ) , in Patientswith Advanced Cancer

S. Alberts, H. Pitot, C. Erlichman, 2005 .

Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.

C. Erlichman, D. Toft, A. McCollum, 2006, Cancer research.

Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies

M. Borad, C. Erlichman, J. Wright, 2016, Investigational New Drugs.

Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.

D. Moore, N. Foster, K. Rowland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.

J. Sloan, M. Goetz, R. Goldberg, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.

J. Sloan, R. Goldberg, A. Adjei, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy.

R. Goldberg, M. O’connell, C. Erlichman, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors

J. Sloan, L. Denis, S. Alberts, 2006, Cancer Chemotherapy and Pharmacology.

Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.

J. Sloan, R. Diasio, R. Goldberg, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An evaluation of postoperative follow-up tests in colon cancer patients treated for cure.

J. O'fallon, P. Novotny, C. Loprinzi, 1997, Oncology.

Optimum doses of irinotecan

M. O’connell, H. Pitot, C. Erlichman, 1999, The Lancet.

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

M. Goetz, J. Krook, K. Rowland, 2007, Clinical colorectal cancer.

The Mayo/NCCTG Experience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer

D. Sargent, R. Goldberg, C. Erlichman, 2003 .

Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.

C. Erlichman, T. Gadalla, A. Wong, 1992, European journal of cancer.

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

S. Mandrekar, M. Goetz, R. Goldberg, 2013, Investigational New Drugs.

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

R. Mesa, C. Erlichman, S. Kaufmann, 2007, Leukemia.

Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation.

H. Llewellyn-Thomas, C. Erlichman, E. Thiel, 1991, Social science & medicine.

Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial

M. Goetz, N. Foster, C. Erlichman, 2012, PloS one.

A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas

D. Ettinger, J. Sarkaria, M. Mahoney, 2011, Cancer.

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

S. Mandrekar, T. Gilmer, K. Flatten, 2008, Clinical Cancer Research.

A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer

S. Mandrekar, H. Pitot, C. Erlichman, 2005, Clinical Cancer Research.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

J. Sloan, R. Marks, R. Goldberg, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer.

P. Philip, M. Mahoney, R. Donehower, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

K. Ballman, C. Erlichman, R. Jenkins, 2008, Cancer research.

Heat shock protein inhibitors increase the efficacy of measles virotherapy

E. Galanis, S. Russell, C. Erlichman, 2008, Gene Therapy.

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

J. Sloan, M. Goetz, A. Adjei, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies

Erin L. Schenk, C. Erlichman, D. Northfelt, 2013, Investigational New Drugs.

A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer

S. Mandrekar, C. Erlichman, A. Adjei, 2006, Clinical Cancer Research.

Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators

J. P. Pignon, Valter Torri, R. Labianca, 1995, The Lancet.

Necrosis in a meningioma following systemic chemotherapy. Case report.

M. Bernstein, C. Erlichman, G. Davidson, 1994, Journal of neurosurgery.

Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication.

E. Eisenhauer, M. Levine, C. Erlichman, 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.

T. Habermann, J. Sloan, S. Ansell, 2002, Blood.

Phase I Study of Interleukin-12 in combination with Rituximab in patients with B-cell non-Hodgkin lymphoma

T. Habermann, J. Sloan, S. Ansell, 2001 .

Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia

J. Sloan, D. Loegering, J. Karp, 2005, Clinical Cancer Research.

Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors

B. Costello, Mojun Zhu, C. Erlichman, 2021, Pancreas.

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

Helen X. Chen, H. Lenz, M. Moore, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Oncology Clinical Trials for Related Subpopulations: The Power Walk Design

S. Cha, J. Sloan, C. Erlichman, 2002 .

Rapid development of enhanced clearance after high‐dose cyclophosphamide

M. Moore, C. Erlichman, J. Thiessen, 1988, Clinical pharmacology and therapeutics.

Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer

M. Moore, C. Erlichman, J. Thiessen, 2004, Cancer Chemotherapy and Pharmacology.

Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.

C. Conover, C. Erlichman, V. Suman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia

Deborah A. Bowen, T. Shanafelt, C. Erlichman, 2013, Cancer.

Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points

J. Sloan, C. Erlichman, S. Kaufmann, 2005, Clinical Cancer Research.

Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

R. Fonseca, A. Dispenzieri, C. Erlichman, 2006, Haematologica.

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

J. Sloan, R. Goldberg, S. Alberts, 2005, Cancer Chemotherapy and Pharmacology.

A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

R. Fonseca, J. Sloan, P. Anderson, 2005, Leukemia.

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies

J. Jett, R. Marks, Shaji K. Kumar, 2013, Investigational New Drugs.

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

S. Mandrekar, S. Alberts, H. Pitot, 2006, Cancer Chemotherapy and Pharmacology.

Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines.

M. Cabot, L. Hartmann, C. Conover, 2003, Molecular pharmacology.

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

J. Buckner, M. Hidalgo, A. Berkenblit, 2010, Investigational New Drugs.

Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study

Deborah A. Bowen, T. Habermann, T. Shanafelt, 2017, American journal of hematology/oncology.

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome

T. Vrtiska, M. Aubry, C. Erlichman, 2005 .

MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

R. Lloyd, M. Mahoney, R. Donehower, 2007 .

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

M. A. Mahr, Minetta C. Liu, D. Visscher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer Estrogen receptor positive breast cancer, neoadjuvant endocrine therapy,

Erica K. Barnell, E. Mardis, O. Griffith, 2017 .

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

J. Dipersio, C. Erlichman, P. Flynn, 2011, Annals of Hematology.

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

M. Millward, H. Pitot, J. Picus, 2013, Clinical genitourinary cancer.

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma

S. Ansell, Hui Tang, C. Erlichman, 2011, Leukemia.

Cancer Therapy : Clinical Phase I Study of Ipilimumab , an Anti – CTLA-4 Monoclonal Antibody , in Patients with Relapsed and Refractory B-Cell Non – Hodgkin Lymphoma

T. Habermann, S. Ansell, I. Lowy, 2009 .

A phase II study of 5‐fluorouracil, leucovorin and interferon‐α in advanced pancreatic cancer

M. Moore, C. Erlichman, L. Kaizer, 1993 .

A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer.

M. Moore, C. Erlichman, L. Kaizer, 1993, Anti-cancer drugs.

Limited Sampling Models for Irinotecan Pharmacokinetics

J. Sloan, H. Pitot, C. Erlichman, 1999 .

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

N. Wolmark, R. Goldberg, A. Grothey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma.

C. Erlichman, C. Wong, B. Cummings, 1996, International journal of radiation oncology, biology, physics.

Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd).

J. Sloan, R. Goldberg, A. Adjei, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Jesse S. Voss, B. Goh, R. Smallridge, 2020, Thyroid : official journal of the American Thyroid Association.

Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma.

C. Erlichman, J. Thiessen, T. Baskerville, 1988, Arzneimittel-Forschung.

Analysis of Phosphoramide Mustard by Reversed‐Phase Ion Pair High Pressure Liquid Chromatography

C. Erlichman, S. Soldin, R. Hardy, 1987, Therapeutic drug monitoring.

High‐Performance Liquid Chromatographic Measurement of Cyclophosphamide in Serum

C. Erlichman, S. Soldin, R. Hardy, 1984, Therapeutic drug monitoring.

Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study

R. Lloyd, M. Mahoney, R. Donehower, 2005 .

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.

C. Erlichman, T. Hobday, J. Rubin, 2005, Mayo Clinic proceedings.

MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

M. Millward, H. Pitot, J. Picus, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.

J. Jett, J. Sloan, R. Goldberg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia.

C. Erlichman, M. Gertz, S. Geyer, 2005, Clinical lymphoma.

A Phase 2 Consortium (P2C) Trial of R115777 (Tipifarnib) in Myelofibrosis with Myeloid Metaplasia.

R. Mesa, C. Erlichman, S. Kaufmann, 2004 .

Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis.

D. Hedley, C. Erlichman, J. Wiley, 1995, British Journal of Cancer.

Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors

B. Costello, M. Borad, S. Alberts, 2014, Investigational New Drugs.

Fluorouracil and leucovorin for metastatic colorectal cancer.

C. Erlichman, 1990, Journal of chemotherapy.

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

R. Fonseca, Shaji K. Kumar, N. Callander, 2015, Blood.

Context-Dependent Antagonism between Akt Inhibitors and Topoisomerase Poisons

D. Loegering, K. Flatten, C. Erlichman, 2014, Molecular Pharmacology.

Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients.

H. Pitot, J. Picus, C. Erlichman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Y. Asmann, F. Huang, K. Flatten, 2011, Molecular Cancer Therapeutics.

Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer

C. Erlichman, D. Warr, T. Gadalla, 2004, Breast Cancer Research and Treatment.

Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

C. Erlichman, K. Bible, S. Ivy, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Akt inhibitor MK2206 selectively targets CLL B‐cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis

Deborah A. Bowen, T. Shanafelt, Shaji K. Kumar, 2014, British journal of haematology.

Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells

C. Erlichman, S. Mandelbaum, J. Pressacco, 2004, Cancer Chemotherapy and Pharmacology.

5-Fluorouracil (FUra) and folinic acid (FA) therapy in patients with colorectal cancer.

C. Erlichman, 1988, Advances in experimental medicine and biology.

Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.

D. Hedley, C. Erlichman, J. Pressacco, 1995, Cancer research.

' Phase J, study of the matrix metalloproteinase inhibitor, BAY 12-956^

J. Sloan, R. Goldberg, S. Alberts, 2001 .

A pilot study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in a phase I clinical trial.

E. Basch, J. Sloan, A. Dueck, 2013 .

Combined radical radiation therapy and chemotherapy for primary squamous cell carcinoma of the anal canal.

C. Erlichman, B. Cummings, G. Thomas, 1982, Cancer treatment reports.

Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.

J. Sloan, R. Goldberg, S. Alberts, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects.

C. Erlichman, J. Pressacco, 1993, Biochemical pharmacology.

Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).

Helen X. Chen, H. Lenz, M. Moore, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.

R. Goldberg, C. Erlichman, 1998, Oncology.

Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil ± leucovorin in MGH-U1 cells

C. Erlichman, B. Mitrovski, 2004, Cancer Chemotherapy and Pharmacology.

Medical Management of Pancreatic Neuroendocrine Tumors

C. Erlichman, T. Hobday, J. Rubin, 2008, The American Journal of Gastroenterology.

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

B. Goh, A. King, S. Leung, 2015, Investigational New Drugs.

Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.

C. Erlichman, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

I. Tannock, N. Boyd, N. Boyd, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract B56: A phase I trial of the combination of dasatinib and lapatinib

M. Borad, C. Erlichman, D. Northfelt, 2009 .

Superiority of methylprednisolone sodium succinate over low dose metoclopramide hydrochloride in the prevention of nausea and vomiting produced by cancer chemotherapy.

D. Osoba, A. Willan, C. Erlichman, 1986, Clinical and investigative medicine. Medecine clinique et experimentale.

Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (HSP90), in patients with advanced solid tumors: Final results.

S. Ramalingam, C. Erlichman, M. Egorin, 2007 .

Oxaliplatin in the treatment of colorectal cancer

C. Erlichman, George P. Kim, 2007, Expert opinion on drug metabolism & toxicology.

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.

C. Erlichman, D. Warr, S. Fine, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer.

S. Mandrekar, M. Goetz, C. Erlichman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose escalation study of the PKC&igr; inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer

A. Mansfield, C. Erlichman, A. Fields, 2013, Anti-cancer drugs.

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

C. Conover, F. Lee, D. Loegering, 2006, Cancer research.

Adjuvant therapy of colon cancer: a review.

C. Erlichman, T. Hobday, Charles Erlichman, 2002, Clinical colorectal cancer.

Ectopic production of human chorionic gonadotropin: a case report.

C. Erlichman, I. Quirt, J. Pringle, 1979, Medical and pediatric oncology.

The clinical case for proton beam therapy

Gary A Ezzell, Michael G Herman, Steven E Schild, 2012, Radiation oncology.

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer

M. Hidalgo, N. Foster, A. Tan, 2012, Cancer medicine.

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

P. Philip, M. Mahoney, R. Donehower, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells

C. Erlichman, Tian-Ling Chen, 2004, Cancer Chemotherapy and Pharmacology.

Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.

R. Donehower, C. Erlichman, B. Chabner, 1982, Journal of the National Cancer Institute.

Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.

J. Karle, C. Erlichman, R. Cysyk, 1980, Cancer research.

Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.

C. Erlichman, D. Vidgen, 1984, Biochemical pharmacology.

An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.

C. Erlichman, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Phase I trial of N-(phosphonacetyl)-L-aspartate.

C. Erlichman, B. Chabner, A. Levine, 1979, Cancer research.

Potential applications of therapeutic drug monitoring in treatment of neoplastic disease by antineoplastic agents.

C. Erlichman, 1986, Clinical biochemistry.

The practical benefits of pharmacokinetics in the use of antineoplastic agents

R. Donehower, C. Erlichman, B. Chabner, 2004, Cancer Chemotherapy and Pharmacology.

Therapeutic Drug Monitoring in Oncology

M. Moore, C. Erlichman, 1987, Clinical pharmacokinetics.

A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.

C. Erlichman, A. Wong, S. Fine, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential methotrexate-fluorouracil: the role of leucovorin in improving tumor response.

C. Erlichman, L. Kaizer, S. Fine, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer.

C. Erlichman, B. Gustavsson, H. Schmoll, 1996, American journal of clinical oncology.

Mitomycin C pharmacokinetics in patients with recurrent or metastatic colorectal carcinoma.

C. Erlichman, A. Rauth, R. Battistella, 1987, Canadian journal of physiology and pharmacology.

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

W. R. Bishop, J. Sloan, J. Sloan, 2000, Cancer research.

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors

C. Erlichman, J. Reid, J. Rubin, 2006, Investigational New Drugs.

Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.

C. Erlichman, A. Tyagi, T. Kensler, 1980, Cancer treatment reports.

Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.

J. Sloan, R. Goldberg, C. Erlichman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2,6-diaminobenz[cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity.

D. Hedley, C. Erlichman, J. Pressacco, 1995, Biochemical pharmacology.

Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

C. Erlichman, S. Kaufmann, A. Adjei, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.

V. Lowe, M. Borad, T. Smyrk, 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

F. Sarkar, S. Sheng, E. Heath, 2008, Clinical Cancer Research.

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in PatientswithHormone-RefractoryMetastatic ProstateCancer

F. Sarkar, S. Sheng, E. Heath, 2008 .

A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer

J. Ingle, E. Galanis, S. Russell, 2006, Breast Cancer Research and Treatment.

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Shaji K. Kumar, N. Callander, C. Erlichman, 2012 .

Male breast cancer: a 13-year review of 89 patients.

C. Erlichman, K. Murphy, T. Elhakim, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

Peter A. Jones, P. Laird, D. Weisenberger, 2017, Oncotarget.

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.

R. Marks, E. Vokes, C. Erlichman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

J. Buckner, M. Hidalgo, C. Erlichman, 2006, Clinical Cancer Research.

Pharmacokinetic Study ofTemsirolimus ( CCI-779 ) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

J. Buckner, M. Hidalgo, C. Erlichman, 2006 .

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.

Andrea K. Kukla, B. Goh, R. Smallridge, 2012, The Journal of clinical endocrinology and metabolism.

Comparison of potential markers of farnesyltransferase inhibition.

C. Erlichman, S. Kaufmann, P. Svingen, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study

H. Pitot, J. Picus, C. Erlichman, 2015, Cancer Chemotherapy and Pharmacology.

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.

C. James, J. Sarkaria, C. Erlichman, 2005, Neoplasia.

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas

R. Lloyd, C. Erlichman, T. Hobday, 2005, Modern Pathology.

Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.

J. Sloan, R. Goldberg, S. Alberts, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

D. Szydlo, P. Philip, T. Mok, 2012, Investigational New Drugs.

Evaluation of Lapatinib andTopotecan CombinationTherapy : Tissue Culture , Murine Xenograft , and Phase I ClinicalTrial Data

T. Gilmer, K. Flatten, C. Erlichman, 2008 .

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

S H Kaufmann, C. James, C. Erlichman, 2001, Cancer research.

A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR): 97

P. Goodman, M. Moore, C. Erlichman, 1994 .

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

M. Hidalgo, C. Erlichman, A. Adjei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice.

C. Erlichman, C Erlichman, D Vidgen, 1984, Cancer research.

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

B. Goh, W. Yeo, Q. Tao, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel Therapeutics in Colorectal Cancer

R. McWilliams, C. Erlichman, 2005, Diseases of the colon and rectum.

Current Status: Novel Therapeutics in Colorectal Cancer

R. McWilliams, C. Erlichman, 2005 .

Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.

S. Ramalingam, C. Erlichman, M. Egorin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Competitive protein binding assay of methotrexate.

R. Donehower, C. Erlichman, C. Myers, 1975, Methods in enzymology.

Small bowel adenocarcinoma: a rare but aggressive disease.

C. Erlichman, P. Limburg, T. Delaunoit, 2004, Clinical colorectal cancer.

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

C. Erlichman, P. Haluska, M. Gottardis, 2008, Molecular Cancer Therapeutics.

Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.

V. Lowe, M. Hung, M. Borad, 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Male breast cancer: An 11 year review of 66 patients

C. Erlichman, Fei-Fei Liu, M. Pintilie, 2005, Breast Cancer Research and Treatment.

A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS).

D. Ettinger, B. Bot, M. Mahoney, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

Erin L. Schenk, B. Costello, L. Doyle, 2021, Investigational New Drugs.

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

D. Gandara, C. Erlichman, A. Adjei, 2019, Investigational New Drugs.

Abstract #3602: Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity

V. Giranda, C. Erlichman, D. Northfelt, 2009 .

Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity

C. Erlichman, S. Kaufmann, P. Svingen, 1998, Cancer Chemotherapy and Pharmacology.

Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors

R. Lloyd, C. Erlichman, T. Hobday, 2006, Endocrine.

Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days

E. Eisenhauer, M. Moore, C. Erlichman, 2004, Investigational New Drugs.

A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal caner

M. Moore, C. Erlichman, R. Feld, 2004, Cancer Chemotherapy and Pharmacology.

What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data

Cristine Allmer, P. Novotny, J. Sloan, 2003 .

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

M. Mahoney, H. Pitot, C. Erlichman, 2008, Investigational New Drugs.

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

D. Loegering, B. Smith, J. Karp, 2009, Cancer research.

Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients

S. Ansell, C. Erlichman, S. Geyer, 2006, Clinical Cancer Research.

A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer

A. Jimeno, M. Hidalgo, R. Donehower, 2008, Clinical Cancer Research.

Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.

S. Steinberg, A. Oza, J. Doroshow, 2012 .

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma

G. Linette, C. Erlichman, V. Suman, 2010, Cancer.

A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study.

P. Philip, R. Lloyd, M. Mahoney, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

A. Feldman, S. Ansell, Hui Tang, 2011, The Lancet. Oncology.

Phase II study of erlotinib in patients with advanced biliary cancer.

P. Philip, M. Mahoney, R. Donehower, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.

J. Sloan, R. Goldberg, H. Pitot, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia

Tait Shanafelt, Diane Jelinek, J. Byrd, 2010, Leukemia & lymphoma.

Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.

D. Osoba, A. Willan, C. Erlichman, 1991, Journal of the National Cancer Institute.

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

J. Sloan, R. Goldberg, S. Alberts, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effects of 5-fluorouracil and leucovorin in spheroids: a model for solid tumours.

C. Erlichman, A. Wu, 1991, Anticancer research.

Development of rational drug combinations with investigational targeted agents.

S. Lutzker, C. Erlichman, J. Zwiebel, 2010, The oncologist.

Differences between accumulation of 99mTc-MIBI and 201Tl-thallous chloride in tumour cells: role of P-glycoprotein.

V. Ling, C. Erlichman, J. Ballinger, 1995, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

Metastatic non-small cell lung carcinoma with involvement of extremity musculature: case report and review of the literature.

C. Erlichman, G. Harms, G. Ramakrishna, 2000, Mayo Clinic proceedings.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

R. Smallridge, C. Erlichman, V. Suman, 2014, The Journal of clinical endocrinology and metabolism.

A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer

J. Sloan, R. Goldberg, S. Alberts, 2002, Investigational New Drugs.

Failure of 5-day vinblastine infusion in the treatment of patients with advanced refractory breast cancer.

I. Tannock, C. Erlichman, I. Quirt, 1982, Cancer treatment reports.

Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.

M. Kahn, R. Fitzgibbons, J. Donohue, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin

J. Sloan, S. Alberts, C. Erlichman, 2005, Anti-cancer drugs.

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma

D. Ettinger, M. Mahoney, P. Fracasso, 2006, Cancer.

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors

M. Saif, C. Erlichman, D. Toft, 2013, Cancer Chemotherapy and Pharmacology.

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

M. Ellis, O. Olopade, Helen X. Chen, 2013, Breast Cancer Research and Treatment.

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

P. Philip, M. Mahoney, H. Pitot, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

P. Philip, M. Mahoney, H. Pitot, 2012, Cancer.

A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

F. Sarkar, S. Sheng, E. Heath, 2005, Clinical prostate cancer.

New treatment options for colorectal cancer.

Daniel J Sargent, D. Sargent, C. Erlichman, 2004, The New England journal of medicine.

Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial

B. Siegel, C. Erlichman, N. Bartlett, 2014 .

Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results

H. Pitot, J. Picus, C. Erlichman, 2007 .

A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study.

J. Herman, S. Baylin, N. Ahuja, 2013 .

A bioassay to measure cytotoxicity of plasma from patients treated with mitomycin C.

C. Erlichman, A. Rauth, R. Marshall, 1985, Cancer research.

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

B. Goh, R. Smallridge, Hui Tang, 2010, The Lancet. Oncology.

RECPAM analysis of prognostic factors in patients with Stage III breast cancer

A. Ciampi, P. Warde, C. Erlichman, 1990, Breast Cancer Research and Treatment.

Novel chemotherapeutic agents in clinical development

C. Erlichman, 1991, Current opinion in oncology.

Cytotoxic and biochemical implications of combining AZT and AG-331

C. Erlichman, J. Pressacco, B. Mitrovski, 2009, Cancer Chemotherapy and Pharmacology.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

L. Hartmann, F. Boakye-Agyeman, A. Chen, 2017, Clinical Cancer Research.

Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.

D. Ettinger, J. Stewart, M. Mahoney, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ICI D1694 and idoxuridine: a synergistic antitumor combination.

D. Hedley, C. Erlichman, J. Pressacco, 1994, Cancer research.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

R. Goldberg, M. O’connell, C. Erlichman, 2001, The New England journal of medicine.

Review of 154 patients with non-functioning pituitary tumors.

W. Simpson, C. Erlichman, J. Meakin, 1979, International journal of radiation oncology, biology, physics.

Phase 2 study of PS-341 (bortezomib) in the treatment of metastatic malignant melanoma (MMM).

P. Fracasso, C. Erlichman, S. Geyer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90

C. Erlichman, 2009, Expert opinion on investigational drugs.

Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol.

C. Erlichman, S. Fine, T. Elhakim, 1986, Cancer treatment reports.

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study

N. Foster, R. McWilliams, C. Erlichman, 2015, Investigational New Drugs.

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

N. Tomita, T. Yamanaka, N. Wolmark, 2021, Journal of the National Cancer Institute.

Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome.

T. Vrtiska, M. Aubry, C. Erlichman, 2005, Mayo Clinic proceedings.

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.

J. Sloan, R. Goldberg, A. Adjei, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy report of a multicenter phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) study

D. Szydlo, P. Philip, M. Mahoney, 2008 .

Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors.

D. V. Von Hoff, M. Saif, C. Erlichman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.

C. Erlichman, S. Kaufmann, L. Karnitz, 2011, Cancer research.

Therapeutics , Targets , and Chemical Biology Poly ( ADP-Ribose ) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells

C. Erlichman, S. Kaufmann, L. Karnitz, 2011 .

A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas.

M. Mahoney, C. Erlichman, W. Maples, 2011, Journal of Clinical Oncology.

Insulin Receptor A and IGF-IR in AML – Response

J. Karp, C. Erlichman, S. Kaufmann, 2010 .

Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449.

M. Borad, A. Grothey, R. McWilliams, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma.

C. Antonescu, N. Foster, G. Schwartz, 2015 .

Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer

C. Erlichman, J. Thiessen, S. Soldin, 2004, Cancer Chemotherapy and Pharmacology.

Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.

R. Smallridge, C. Erlichman, V. Suman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

Andrea K. Kukla, A. Oberg, L. Doyle, 2012, Gynecologic oncology.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

D. Steensma, R. Mesa, D. Loegering, 2011, Haematologica.

A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients.

S. Mandrekar, A. Adjei, C. Erlichman, 2004, Journal of Clinical Oncology.

Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET).

Helen X. Chen, C. Erlichman, T. Hobday, 2015 .

A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

C. Erlichman, P. Flynn, B. Laplant, 2015, Leukemia & lymphoma.

Antineoplastic drug cytotoxicity in a human bladder cancer cell line: Implications for intravesical chemotherapy

C. Erlichman, C. Erlichman, D. Vidgen, 1987, Urological Research.

A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.

C. Erlichman, A. Adjei, 1999, Seminars in oncology.

[30] Competitive protein binding assay of methotrexate

R. Donehower, C. Erlichman, C. Myers, 1982 .

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma

Helen X. Chen, A. El-Khoueiry, T. Bekaii-Saab, 2015, Investigational New Drugs.

A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7)

S. Mandrekar, M. Goetz, R. Goldberg, 2005 .

A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer

C. Rudin, R. Govindan, A. Argiris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I trial of dasatinib (D) and lapatinib (L).

R. Marks, C. Erlichman, D. Northfelt, 2010 .

Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

Y. Asmann, C. T. Eyck, C. Erlichman, 2009 .

Phase II trial of R-(-)-gossypol acetic acid (NSC 726190, AT-101) in patients with recurrent extensive stage small cell lung cancer (ES-SCLC).

R. Govindan, A. Argiris, M. Millward, 2010 .

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

R. Mesa, D. Loegering, H. Powell, 2005 .

Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.

C. Erlichman, B. Chabner, J. Strong, 1980, Cancer research.

A phase I study of once-weekly aminoflavone prodrug (AFP464) in solid tumor patients.

M. Goetz, C. Erlichman, J. Reid, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.